Key result
Probucol with a 3-day premedication protocol did not significantly reduce angiographic stent restenosis compared to control (21% vs. 24%; P = 0.81).
Why the study?
Does probucol prevent angiographic restenosis in patients with coronary artery disease undergoing coronary stenting?
RCT (n=78)
randomized
Does probucol prevent angiographic restenosis in patients with coronary artery disease undergoing coronary stenting?
A 3-day premedication protocol with probucol followed by continuous administration does not reduce angiographic restenosis after coronary stenting.
Answers are grounded in this paper and cite their sources.
Short-course probucol adds no value for stent restenosis prevention; confirms ineffectiveness of this antioxidant approach in coronary stenting.
Probucol is a lipid-lowering drug that has an antioxidant effect. The authors sought to investigate the effect of probucol on stent restenosis after the usual 3-day pretreatment protocol. From March 1999 to August 2000, 78 patients (mean age, 56 +/- 8; 49 male) with coronary artery disease who underwent coronary stenting were enrolled. After a diagnostic angiography was done, each eligible patient was randomized to either the probucol or the control group. Following the procedure, ticlopidine was administered for 1 month; aspirin and probucol continuously. Angiographic follow-up was done in 81% (57/70) and angiographic restenosis was not different between the two groups (21% vs. 24%; P = 0.81). In conclusion, antioxidant probucol did not show a beneficial effect on stent restenosis with 3 days of premedication protocol.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2002) conducted an RCT in coronary artery disease (n=78). Probucol vs. control was evaluated on angiographic restenosis (p=0.81). Probucol with a 3-day premedication protocol did not significantly reduce angiographic stent restenosis compared to control (21% vs. 24%; P = 0.81).
Synapse has enriched 10 related papers. Consider them for comparative context: